AGC Biologics will commence cell therapy process development and clinical manufacturing services at AGC Inc.’s Yokohama ...

Incyte Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of ...

As the pharmaceutical industry continues to evolve, so too does the role of secondary packaging. From serialization and ...

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies, has transferred the upstream phase of the manufacturing process for LUMEVOQ, its gene ...

Silo Pharma Inc. has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth ...

MAIA Biotechnology Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

Gilead Sciences Inc. and Kymera Therapeutics Inc. have entered into an exclusive option and license agreement.

The cost of a failed CDMO relationship isn’t just financial. It’s strategic. It delays clinical timelines. It erodes investor ...

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

Xcell Biosciences, an instrumentation company focused on cell and gene therapy applications, has partnered with Thermo Fisher ...

Precision BioSciences, Inc. received a Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for PBGENE-DMD to treat Duchenne muscular dystrophy (DMD).